Endocrine System Diseases × Clear all
NCT03899792 2026-01-06

LIBRETTO-121

Eli Lilly and Company

Phase 1/2 Active not recruiting
36 enrolled 13 charts 2 FDA
NCT03157128 2025-10-20

LIBRETTO-001

Eli Lilly and Company

Phase 1/2 Active not recruiting
857 enrolled 3 FDA
NCT03093116 2025-07-10

TRIDENT-1

Turning Point Therapeutics, Inc.

Phase 1/2 Recruiting
500 enrolled 2 FDA
NCT03037385 2025-05-31

ARROW

Hoffmann-La Roche

Phase 1/2 Completed
590 enrolled 58 charts 5 FDA
NCT05638269 2024-07-29

A Multicentre Study on Features of the Gut Microbiota of Patients With Critical Chronic Diseases in China

Zhujiang Hospital

Recruiting
12,000 enrolled
NCT04949282 2022-12-23

SEPTRALU

Sociedad Española de Medicina Nuclear e Imagen Molecular

Recruiting
5,000 enrolled
NCT03562897 2022-07-06

Evaluation of Ocoxin-Viusid® in Advanced or Metastatic Ovarian Epithelial Cancer

Catalysis SL

Phase 2 Completed
40 enrolled
NCT01215578 2015-04-30

NET

Assistance Publique - Hôpitaux de Paris

Phase 2 Terminated
33 enrolled